Last reviewed · How we verify
KN035
At a glance
| Generic name | KN035 |
|---|---|
| Sponsor | 3D Medicines (Sichuan) Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors (PHASE1, PHASE2)
- ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors (PHASE2)
- KN035 for dMMR/MSI-H Advanced Solid Tumors (PHASE2)
- Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC (PHASE3)
- Study to Evaluate Safety, Tolerance and Efficacy of ASC22 Combined With ART in Subjects With HIV (PHASE2)
- Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC. (PHASE2)
- ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma (PHASE2)
- Endostar Combined With SBRT and Envafolimab in the Treatment of Advanced Gastrointestinal Tumors (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KN035 CI brief — competitive landscape report
- KN035 updates RSS · CI watch RSS
- 3D Medicines (Sichuan) Co., Ltd. portfolio CI